IP Library Granted Patent US 9,980,996
Granted Patent B2
US 9,980,996 · App. 14/694,303 · Granted May 29, 2018

Pharmaceutical composition and method of manufacturing

Inventor: Gary J. Speier (Eden Prairie, MN)
A61K36/185A61K9/006A61K9/7023A61K31/352A61K36/00A61K2236/37
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,980,996
App. No.
14/694,303
Granted
May 29, 2018
Kind
B2
Abstract

The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis . The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis , as well as methods of medical treatment that include administering the pharmaceutical dosage forms.

Claims (59)

1. A process for obtaining a concentrate of Cannabis sativa or Cannabis indica , the process comprising:

(a) contacting Cannabis sativa or Cannabis indica plant material with a supercritical fluid solvent system, at a pressure between about 750 psi and 25,000 psi, and at a temperature between about −15° C. and 200° C., to provide an extract of Cannabis sativa or Cannabis indica ; and

(b) removing the supercritical fluid solvent system from the extract;

wherein the (a) contacting of the Cannabis sativa or Cannabis indica plant material with the supercritical fluid solvent system and the (b) removing the supercritical fluid solvent system, is carried out multiple times, such that the process is a fractional supercritical fluid extraction;

wherein each contacting of the Cannabis sativa or Cannabis indica with a supercritical fluid solvent system independently occurs at a pressure between about 750 psi and 25,000 psi, and independently occurs at a temperature between about −15° C. and 200° C.;

wherein at least one of the supercritical fluid extractions is carried out at a pressure of at least about 8,000 psi; and

wherein each supercritical fluid solvent system independently comprises carbon dioxide (CO 2 ) and optionally one or more additional solvents and optionally one or more co-solvents, selected from the group consisting of hydrogen (H 2 ), neon (Ne), nitrogen (N 2 ), argon (Ar), methane (CH 4 ), ethane (CH 3 CH 3 ), propane (CH 3 CH 2 CH 3 ), ammonia (NH 3 ), water (H 2 O), xenon (Xe), methanol, ethanol, 1-propanol, 2-propanol, 1-hexanol, 2-methoxy ethanol, tetrahydrofuran (THF), 1,4-dioxane, acetonitrile, methylene chloride, dichloroethane, chloroform, ethyl acetate, propylene carbonate, N,N-dimethylaceamide, dimethyl sulfoxide (DMSO), formic acid, carbon disulfide, acetone, toluene, hexanes, pentanes, trifluoromethane (Freon® 23), nitrous oxide (N 2 O), sulfur hexafluroide (SF 6 ), butane (n-C 4 H 10 ), isobutane (i-C 4 H 10 ), ethyl ether ((C 2 H 5 ) 2 O), benzotrifluoride (C 6 H 5 CF 3 ), p-chlorophenyl trifluoromethane (ClC 6 H 4 CF 3 ), chlorofluorocarbon (CFC), hydrofluorocarbon (HFA), HFA-134a (1,1,1,2-tetrafluoroethane), and mixtures thereof.

2. The process of claim 1 , wherein each pressure is independently selected from (i) 750-4,000 psi, (ii) 4,000-7,000 psi, and (iii) 7,000-25,000 psi; with the proviso that at least one of the supercritical fluid extractions is carried out at a pressure of at least about 8,000 psi.

3. The process of claim 1 , wherein each temperature is independently selected from (i) −15-70° C., (ii) 70-100° C., and (iii) 100-200° C.

4. The process of claim 1 , wherein each fractional supercritical fluid extraction is independently carried out employing a supercritical fluid solvent system which is: (i) polar aprotic, (ii) polar protic, (iii) nonpolar aprotic, or (iv) nonpolar protic.

5. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica comprises at least one of:

cannabinol (CBN),

cannabinolic acid (CBNA),

Δ(9)-tetrahydrocannabinol (Δ(9)-THC),

Δ(9)-tetrahydrocannabinolic acid (Δ(9)-THCA),

Δ(9)-cannabidiol (Δ(9)-CBD),

Δ(9)-tetrahydrocannabidiolic acid (Δ(9)-CBDA),

Δ(8)-tetrahydrocannabinol (Δ(8)-THC),

Δ(8)-tetrahydrocannabinolic acid (Δ(8)-THCA),

Δ(8)-tetrahydrocannabidiol (Δ(8)-CBD),

Δ(8)-tetrahydrocannabidiolic acid (Δ(8)-CBDA),

Δ(9)-tetrahydrocannabivarin (Δ(9)-THV),

cannabigerol (CBG),

cannabigerolic acid (CBGA),

cannabichromene (CBC),

cannabichromenic acid (CBCA),

cannabicyclol (CBL),

cannabicyclolic acid (CBLA),

β-caryophyllene epoxide,

mentha-1,8(9)-dien-5-ol,

pulegone,

limonene,

limonene oxide,

α-terpinene,

terpinen-4-ol,

carvacrol,

carvone,

1,8-cineole,

p-cymene,

fenchone,

pulegone-1,2epoxide,

β-myrcene,

cannaflavin A, and

cannaflavin B.

6. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica , relative to the Cannabis sativa or Cannabis indica plant material, is at least partially purified from at least one of terpenes, alkaloids, hemp oil, and cannabinoid acids.

7. The process of claim 1 , further comprising purifying the concentrate of Cannabis sativa or Cannabis indica , employing at least one of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, and sublimation.

8. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica comprises Δ(9)-tetrahydrocannabinol (Δ(9)-THC).

9. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica comprises Δ(9)-tetrahydrocannabinolic acid (Δ(9)-THCA).

10. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica comprises Δ(9)-cannabidiol (Δ(9)-CBD).

11. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica Δ(9)-tetrahydrocannabidiolic acid (Δ(9)-CBDA).

12. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica comprises Δ(8)-tetrahydrocannabinol (Δ(8)-THC).

13. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica comprises Δ(8)-tetrahydrocannabinolic acid (Δ(8)-THCA).

14. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica comprises Δ(8)-tetrahydrocannabidiol (Δ(8)-CBD).

15. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica comprises Δ(8)-tetrahydrocannabidiolic acid (Δ(8)-CBDA).

16. The process of claim 1 , wherein the concentrate of Cannabis sativa or Cannabis indica comprises Δ(9)-tetrahydrocannabivarin (Δ(9)-THV).

17. The process of claim 1 , wherein any one or more supercritical fluid solvent system independently comprises an additive selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, 1-hexanol, 2-methoxy ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, ammonia, chloroform, propylene carbonate, N,N-dimethylaceamide, dimethyl sulfoxide, formic acid, water, carbon disulfide, acetone, propane, toluene, hexanes, pentanes, C 6 H 5 CF 3 , p-ClC 6 H 4 CF 3 , and mixtures thereof.

18. The process of claim 1 , wherein the first fractional supercritical fluid extraction is carried out with carbon dioxide (CO 2 ) as the sole solvent.

19. The process of claim 1 , wherein the second fractional supercritical fluid extraction is carried out with carbon dioxide (CO 2 ) as the sole solvent.

20. The process of claim 1 , wherein the first concentrate is enriched with tetrahydrocannabinols (THCs) and the second concentrate is enriched with cannabidiols (CBDs).

Assignments (3)
SECURITY INTEREST Recorded Oct 18, 2024
From: AVENIR WELLNESS SOLUTIONS, INC.
To: SINDERBRAND LAW GROUP, PC
Reel/Frame 068937/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2023
From: AVENIR WELLNESS SOLUTIONS, INC. F/K/A CURE PHARMACEUTICAL HOLDING CORPORATION
To: AVENIR WELLNESS SOLUTIONS, INC.
Reel/Frame 063663/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2018
From: SPEIER, GARY J.
To: CURE PHARMACEUTICAL HOLDING CORP.
Reel/Frame 046512/0531 →
Continuity (2)
Continuation 14255296 · Apr 17, 2014
Related Publication 20150297653A1 · Oct 22, 2015